Pushing lower boundaries

GAITHERSBURG, Md.—Microdosing specialist Xceleron announced an agreement with Neurocrine Biosciences for a multi-arm Phase 0 study

Apr 12, 2006|1 min read

Randall C Willis

Listen with Speechify

0:00

5:00

GAITHERSBURG, Md.—Microdosing specialist Xceleron announced an agreement with Neurocrine Biosciences for a multi-arm Phase 0 study that will evaluate preliminary pharmacokinetics (PK) and metabolism of five compounds. Xceleron will conduct clinical trials in Europe with accelerator mass spectrometry analysis completed at the company's GLP accredited laboratories in York, U.K.

"Partnering with Xceleron to bring our drug candidates into clinical development early in the development process provides Neurocrine with significant benefits in terms of or additional candidate selection as well as reduced risk and cost," said Dr. Haig Bozigian, Neurocrine's vice president of preclinical development. "While our lead compound is being evaluated in clinical studies, microdose studies will provide additional valuable comparative pharmacokinetics and bioavailability for our back-up compounds."